News

Reliability Findings from the Unified Global Training Program for the Brief Negative Symptoms Scale (BNSS)

MedAvante-ProPhase presented an analysis of reliability in administration of the Brief Negative Symptoms Scale (BNSS) across multiple studies and countries at the 14th International Society for CNS Clinical Trials and Methodology (ISCTM) Scientific Conference. BNSS achieved overall good-to-excellent inter-rater reliability among raters from different countries and cultures.

Continue reading

Simplified Negative and Positive Symptoms Interview (SNAPSI): An Abbreviated Assessment Technique for Schizophrenia Studies

Analysis of the methodological question can the PANSS be modified to be useable in clinical settings as well as in research? presented at the 14th ISCTM Scientific Conference. Authors propose PANSS-6 rating, guided by SNAPSI, to bridge the gap between research and clinical care in schizophrenia.

Continue reading

Identifying Elevated Rates of CDR Scoring Errors: The Cognitive-Functional Difference Score

At 10th Clinical Trials on Alzheimer’s Disease (CTAD) MedAvante-ProPhase presented research and analysis addressing the need to identify administrations of the Clinical Dementia Rating scale (CDR) within clinical trials that have an increased probability of scoring errors to maintain data integrity and improve signal detection.

Continue reading

Subjective Interview Quality Metrics Predict Scoring Performance in the Administration of the PANSS

MedAvante presented research at the 30th European College of Neuropsychopharmacology (ECNP) Congress showing that subjective interview quality metrics are predictive of in-study scoring performance and can serve as a useful tool in ongoing monitoring of raters in the administration and scoring of the PANSS. When combined with eCOA administration to improve standardization, subjective quality metrics can increase signal detection in global schizophrenia clinical trials.

Continue reading

Impact of Centralized Over-Read on Outcomes in Depression and Schizophrenia Trials

Research presented at the 2017 International Society for CNS Clinical Trials and Methodology (ISCTM) Fall Conference examined Central Review of two widely used efficacy measures administered in schizophrenia and depression trials, the Positive and Negative Syndrome Scale (PANSS) and Hamilton Depression Rating Scale (HAM-D), resulting in positive impact on individual item scores and total scale score for key study visits, improving interrater reliability and reducing rater drift.

Continue reading

The RBANS as a Useful Outcome Measure in Prodromal AD Trials

The RBANS total scale index score correlated with the CDR-SB, and decreased in a linear fashion with increasing CDR-SB, even within a limited range of CDR-SB scores and without evidence of floor or ceiling effects.

Continue reading